$SCNI News

Last published 3w ago

3w agoSCNIScinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed FinancingPR NewswireManagement estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and deliveredJERUSALEM, Oct.
3w agoSCNIScinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant InducementPR NewswireJERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing
4w agoSCNIScinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant InducementPR NewswireJERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and
4w agoSCNIScinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing AgreementPR NewswireCommitted Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in
1mo agoSCNIScinai Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic...
2mo agoSCNIScinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO BusinessPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative immunology therapeutic...
2mo agoSCNIScinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO MomentumPR NewswireInvestor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:...
3mo agoSCNIScinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process AdministrationPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative...
5mo agoSCNIScinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth InitiativesPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development...
5mo agoSCNIScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO FacilityPR NewswireJERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company...
6mo agoSCNIScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit EuropePR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today...
6mo agoSCNIScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative...
7mo agoSCNIScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology...
7mo agoSCNIScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model...
7mo agoSCNIScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology...
8mo agoSCNIScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PricePR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq...
8mo agoSCNIScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option...
8mo agoSCNIScinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish PlatformPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel...
8mo agoSCNIScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with RecipharmPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I)...
10mo agoSCNIScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthILPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) ...
11mo agoSCNIScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline AdvancesPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and...
1y agoSCNIScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO CapabilitiesPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company with a growing boutique contract development...
1y agoSCNIScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative...
1y agoSCNIScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) biological products and...
1y agoSCNIScinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
1y agoSCNIScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering...
1y agoSCNIScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.PR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
1y agoSCNIScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative...
1y agoSCNIScinai Announces Annual Financial Results for 2024PR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative...
1y agoSCNIScinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin DiseasesPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
1y agoSCNIScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological ConditionsPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
1y agoSCNIScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025PR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
1y agoSCNISCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENTPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
1y agoSCNIScinai to Connect with Investors and Pharma Leaders at Upcoming Key US ConferencesPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology...
1y agoSCNIScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
1y agoSCNIProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory BoardPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of...
1y agoSCNIDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory BoardPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and...
1y agoSCNIScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 millionPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2y agoSCNIScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and...
2y agoSCNIScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH AntibodiesPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology...
2y agoSCNIIBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.GlobeNewswireLOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the
2y agoSCNIScinai Regains Full Compliance with Nasdaq Listing RequirementsPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2y agoSCNIScinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI; "Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2y agoSCNIScinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoSCNIScinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing ShareholderPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2y agoSCNIScinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23PR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and...
2y agoSCNIScinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common EquityPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I)...
2y agoSCNIScinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAbPR NewswireScinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
2y agoSCNIScinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin modelPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...
2y agoSCNIScinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to EquityPR NewswireScinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I)...